Suits Against Reglan Generics Can't Skirt Mensing: NJ Court

Law360, New York (May 9, 2012, 7:38 PM EDT) -- A New Jersey court on Friday dismissed a Wockhardt Ltd. subsidiary from litigation claiming versions of the heartburn medication Reglan caused users to develop a neurological disorder, rejecting a theory advanced by plaintiffs nationwide attempting to dodge the U.S. Supreme Court's Mensing decision.

The plaintiffs in the instant suit contended that Morton Grove Pharmaceuticals Inc. became the de facto brand-name manufacturer of the syrup form of Reglan when the U.S. Food and Drug Administration named the company's product as the reference point for establishing bioequivalency —...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.